En Bloc Minimal Laser Resection for T3-Chest Wall Lung Cancer in Patients with Poor Pulmonary Function

CHEST Journal ◽  
1996 ◽  
Vol 110 (4) ◽  
pp. 1092-1096 ◽  
Author(s):  
Tommaso Claudio Mineo ◽  
Vincenzo Ambrogi ◽  
Eugenio Pompeo ◽  
Italo Nofroni ◽  
Carlo U. Casciani
ASVIDE ◽  
2020 ◽  
Vol 7 ◽  
pp. 24-24
Author(s):  
Dany Balke ◽  
Varun Gupta ◽  
Stefan Welter

2018 ◽  
Vol 67 (04) ◽  
pp. 299-305 ◽  
Author(s):  
Marco Chiappetta ◽  
Dania Nachira ◽  
Maria Teresa Congedo ◽  
Elisa Meacci ◽  
Venanzio Porziella ◽  
...  

Background The aim of this study was to identify prognostic factors in patients affected by non-small cell lung cancer (NSCLC) with chest wall (CW) involvement, analyzing different strategies of treatment and surgical approaches. Methods Records of 59 patients affected by NSCLC with CW involvement underwent surgery were retrospectively reviewed, from January 2000 to March 2013. Results Induction therapy was administered to 18 (30.5%) patients while adjuvant treatment to 36 (61.0%). In 36 (61%) patients, lung resection was associated only with a parietal pleural resection while in 23 (39%) with CW en-bloc resection. Overall 5-year survival was 34%. Prognostic factors were evaluated in the 51 (86.4%) completely resected (R0) patients.Five-year survival was 60% in patients undergoing induction therapy followed by surgery and 24% in those who underwent surgery as first treatment (p = 0.11). Five-year survival was better in the neoadjuvant group than that in the surgery group in IIB (T3N0) p-stage (100 vs 28%, p = 0.03), while in the IIIA (T3N1–2,T4N0) p-stage it was of 25 vs 0%, respectively (p = 0.53).No 5-year survival difference was found in case of parietal pleural resection versus CW en-bloc resection (p = 0.27) and in case of only parietal pleural involvement versus soft tissue (p = 0.78).In case of incomplete resection (R1), patients undergoing adjuvant radiotherapy had better 2-year survival than patients untreated: 60% vs 0% (p = 0.025). Conclusions Type of surgical resection and the deep of infiltration of disease do not influence survival in this subset of patients. Integrated treatments seem to be suitable: neoadjuvant therapies ensure a better survival rate than surgery alone in IIB and IIIA patients, instead adjuvant radiotherapy proves a fundamental option in incomplete resections.


2008 ◽  
Vol 85 (2) ◽  
pp. S733-S736 ◽  
Author(s):  
Robert J. McKenna ◽  
Ali Mahtabifard ◽  
Johnnie Yap ◽  
Robert McKenna ◽  
Clark Fuller ◽  
...  

2014 ◽  
Vol 9 (1) ◽  
Author(s):  
Heron Teixeira Andrade Santos ◽  
Agnaldo José Lopes ◽  
Cláudio Higa ◽  
Rodolfo Acatauassú Nunes ◽  
Eduardo Haruo Saito

2020 ◽  
Vol 58 (3) ◽  
pp. 598-604
Author(s):  
Alessandro Gonfiotti ◽  
Lavinia Gatteschi ◽  
Alberto Salvicchi ◽  
Stefano Bongiolatti ◽  
Federico Lavorini ◽  
...  

Abstract OBJECTIVES There is currently a lack of clinical data on the novel beta-coronavirus infection [caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] and concomitant primary lung cancer. Our goal was to report our experiences with 5 patients treated for lung cancer while infected with SARS-CoV-2. METHODS We retrospectively evaluated 5 adult patients infected with SARS-CoV-2 who were admitted to our thoracic surgery unit between 29 January 2020 and 4 March 2020 for surgical treatment of a primary lung cancer. Clinical data and outcomes are reported. RESULTS All patients were men with a mean age of 74.0 years (range 67–80). Four of the 5 patients (80%) reported chronic comorbidities. Surgery comprised minimally invasive lobectomy (2 patients) and segmentectomy (1 patient), lobectomy with en bloc chest wall resection (1 patient) and pneumonectomy (1 patient). Mean chest drain duration was 12.4 days (range 8–22); mean hospital stay was 33.8 days (range 21–60). SARS-CoV-2-related symptoms were fever (3 patients), persistent cough (3 patients), diarrhoea (2 patients) and syncope (2 patients); 1 patient reported no symptoms. Morbidity related to surgery was 60%; 30-day mortality was 40%. Two patients (1 with a right pneumonectomy, 74 years old; 1 with a lobectomy with chest wall resection and reconstruction, 70 years old), developed SARS-CoV-2-related lung failure leading to death 60 and 32 days after surgery, respectively. CONCLUSIONS Lung cancer surgery may represent a high-risk factor for developing a severe case of coronavirus disease 2019, particularly in patients with advanced stages of lung cancer. Additional strategies are needed to reduce the risk of morbidity and mortality from SARS-CoV-2 infection during treatment for lung cancer.


Lung Cancer ◽  
2000 ◽  
Vol 29 (1) ◽  
pp. 139
Author(s):  
P.P Brega Massone ◽  
C Lequaglie ◽  
B Conti ◽  
B Magnani ◽  
I Cataldo

2004 ◽  
Vol 100 (4) ◽  
pp. 353-357 ◽  
Author(s):  
Masashi Komagata ◽  
Makoto Nishiyama ◽  
Atshuhiro Imakiire ◽  
Hirobumi Kato

✓ Lung cancers invading the chest wall and spinal column are often considered unresectable, and consequently there are few reports describing resection of invasive vertebral lesions. The authors developed a new anterior approach procedure for the en bloc resection of primary lung adenocarcinoma invading the thoracic spine and chest wall, in which the primary tumor does not need to be separated from the vertebrae. The authors describe a total spondylectomy for the en bloc resection of lung cancer invading the spine. A combination of surgical techniques was required, including resection of the osseous elements T-2 and T-3 (the pedicles were excised using a thread saw), anterolateral thoracotomy, apical lobectomy, chest wall resection, vertebrectomy, anterior spinal column reconstruction with a titanium mesh cage containing bioactive glass ceramic, and placement of anterior and posterior spinal instrumentation. At 46 months after surgery, there is no evidence of local recurrence or distant metastasis, and the patient continues to improve. This new procedure allows for the en bloc resection of primary lung tumors and adherent vertebral invasion without separation of the lesion from the vertebra. Thus, surgical management by complete excision of Pancoast tumors can achieve longer-term survival rates without sequelae.


2004 ◽  
Vol 18 (1) ◽  
pp. 58-63
Author(s):  
Hiroyuki Ito ◽  
Kenji Inui ◽  
Naoki Goto ◽  
Kazuhiro Sakamoto ◽  
Yoshinori Takanashi

Sign in / Sign up

Export Citation Format

Share Document